Login to Your Account



Extracting Value

Activist Investor Pushes Celera to Divest Merck Bone Drug Royalties

By Trista Morrison


Wednesday, February 10, 2010
The Biotechnology Value Fund (BVF), a historically activist investor group, revealed in a 13-D filing Tuesday the reason for its recent interest in diagnostics firm Celera Corp.: BVF wants Celera to spin out its royalty interest in Merck & Co. Inc.'s Phase III osteoporosis drug, odanacatib. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription